When Will GLP-1 Pills Arrive? Outlook for Oral Weight-Loss Drugs

One-line summary: oral GLP-1 weight-loss drugs are still in the development and approval stage

Most GLP-1 obesity and diabetes treatments currently prescribed in Korea are once-weekly subcutaneous injections. Wegovy (semaglutide) is an injectable drug indicated for obesity, while Mounjaro (tirzepatide) is a dual GIP/GLP-1 injectable. The “oral pill-type GLP-1 weight-loss drug” many people are curious about is Eli Lilly’s orforglipron, which has completed phase 3 clinical trials and is now in the approval process, meaning development and regulatory review. It has not yet been generally launched. The exact launch timing, price, and Korean brand name have not been confirmed and may change, so please use this article only as a broad overview and check the latest news.

Which GLP-1 drugs are currently used in Korea?

• Wegovy (semaglutide, Novo Nordisk): once-weekly subcutaneous injection, indicated for obesity treatment, launched in Korea in 2024. Ozempic and Saxenda are also Novo Nordisk GLP-1 drugs.
• Mounjaro (tirzepatide, Eli Lilly): dual GIP/GLP-1 action, once-weekly subcutaneous injection. In Korea, it was launched for the diabetes indication in 2024-2025, while in the United States it is sold for the obesity indication under a separate brand name, Zepbound.
• Common point: all are injectable formulations and are prescription medicines prescribed at a doctor’s discretion when indications such as BMI criteria are met.

The “oral” GLP-1: what kind of drug is orforglipron?

Orforglipron is an investigational GLP-1 drug taken as a pill by mouth. Existing GLP-1 drugs have a protein, or peptide, structure and are easily broken down in the stomach, so they have to be injected. Orforglipron is known for being designed as a small-molecule, non-peptide drug that can be taken as a pill. However, it is currently in the approval process after phase 3 clinical trials and has not yet been marketed for general use. Final evaluation of efficacy and safety, as well as regulatory approval procedures, remain, so outcomes may change.

Mechanism: why does appetite decrease?

GLP-1 is a hormone naturally secreted after meals. It sends satiety signals and slows the rate at which the stomach empties. GLP-1 drugs mimic this action, suppressing appetite and delaying gastric emptying to help reduce food intake naturally. Mounjaro-type drugs use a dual-action approach that also stimulates another hormone pathway called GIP. The key point is that these drugs are not “magic” that replaces willpower; they act on the physiological mechanism of appetite regulation.

Effects vary greatly by individual

Clinical trials have reported meaningful average weight loss, but these figures are only averages of about a certain level, and individual differences are very large. Even with the same drug at the same dose, responses vary from person to person, and results differ when diet, exercise, and other lifestyle measures are also managed. They should not be taken as a promise that a specific percentage of weight loss will occur. It is also important to know that after stopping the drug, appetite may return and weight may increase again, known as rebound.

Side effects and contraindications: points worth knowing

• Common side effects: gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. These usually appear while the dose is being increased gradually.
• Rare but important side effects: pancreatitis and gallstones have been reported.
• Boxed warning in the United States: a warning is included because thyroid C-cell tumors were observed in animal rodent studies.
• Contraindications: these drugs should not be used by people with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
• Other points: use during pregnancy, interactions with other drugs, and related issues should be discussed with medical professionals whenever possible.

Prescription eligibility and caution against misuse

These drugs are prescription medicines, not diet supplements. In general, doctors prescribe them only when obesity indications are met, such as BMI criteria or overweight with related conditions, after weighing risks and benefits. Arbitrary use for cosmetic reasons, such as simply wanting to become a little slimmer, or attempts to obtain the drug without matching the indication are not recommended.

Cost: it may be expensive and not covered by insurance

GLP-1 drugs used for obesity treatment are often not covered by national health insurance, which can create a large out-of-pocket burden for patients. Even if an oral GLP-1 drug is launched in the future, its price and insurance coverage will be decided separately at launch and are not confirmed at present. Specific costs vary by timing and medical institution, so they should be checked at the actual prescription stage.

Summary: when might an oral weight-loss drug arrive?

1. Injectable GLP-1 obesity drugs such as Wegovy and diabetes drugs such as Mounjaro are already prescribed in Korea.
2. The oral pill-type GLP-1 orforglipron is in the approval process after phase 3 clinical trials and has not yet been launched.
3. Launch timing, price, Korean brand name, and insurance coverage are all unconfirmed and may change, so check the latest news and official announcements from the Ministry of Food and Drug Safety and the manufacturer before making decisions.
4. For any formulation, it is safest to decide whether to receive a prescription or take the drug through consultation with a doctor or pharmacist.

Important notice

This article is for general medical information only and does not replace diagnosis or prescription. All drugs mentioned here are prescription medicines that require a doctor’s prescription, and they are not diet supplements. Whenever possible, consult a doctor or pharmacist before starting, stopping, or changing the dose, and receive advice suited to your health condition and medical history. Launch and pricing information for drugs in development may change, so always check the latest official information.